Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has received a consensus rating of "Moderate Buy" from the fourteen research firms that are presently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $30.56.
A number of research firms have recently commented on KROS. Bank of America downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $32.00 to $18.00 in a report on Tuesday, June 10th. Scotiabank decreased their price objective on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday, May 12th. Truist Financial dropped their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Wedbush restated a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a report on Friday, May 30th. Finally, HC Wainwright lowered their price target on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, May 8th.
Read Our Latest Analysis on KROS
Insider Activity
In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider owned 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 22.90% of the company's stock.
Institutional Trading of Keros Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its stake in Keros Therapeutics by 2.6% during the 4th quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company's stock valued at $1,549,000 after acquiring an additional 2,462 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Keros Therapeutics by 7.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 279,682 shares of the company's stock worth $4,427,000 after purchasing an additional 19,562 shares during the last quarter. AlphaQuest LLC grew its stake in Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after purchasing an additional 2,964 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Keros Therapeutics in the fourth quarter worth about $461,000. Finally, Swiss National Bank increased its holdings in Keros Therapeutics by 4.8% in the fourth quarter. Swiss National Bank now owns 59,000 shares of the company's stock valued at $934,000 after buying an additional 2,700 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.
Keros Therapeutics Price Performance
NASDAQ:KROS traded down $0.05 during mid-day trading on Friday, reaching $13.40. The company's stock had a trading volume of 517,755 shares, compared to its average volume of 863,690. The stock has a market cap of $544.31 million, a P/E ratio of -74.44 and a beta of 1.26. The company's fifty day simple moving average is $14.00 and its two-hundred day simple moving average is $12.82. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $3.63. The company had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a net margin of 1.96% and a return on equity of 0.75%. During the same period in the previous year, the company earned ($1.21) EPS. Sell-side analysts expect that Keros Therapeutics will post -4.74 EPS for the current fiscal year.
About Keros Therapeutics
(
Get Free ReportKeros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Featured Articles

Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.